Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study
Authors:
- 19 August 2019
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 21 (9) , 499-506
Abstract
Background: Experience from first-generation closed-loop (CL) systems informs refinements to enhance glucose control and user acceptance. A next-generation prototype enhanced-hybrid CL (E-HCL) system incorporates iterative changes to the Medtronic MiniMed 670G CL system, including automated correction boluses, lower target glucose level, and user enhancements. The aim was to explore safety, system performance, and glucose control using E-HCL in adults with type 1 diabetes. Methods: Twelve adults underwent this first in-human feasibility study. After a 1-week run-in using open-loop (OL), E-HCL was activated at the start of a supervised 1-week hotel phase, followed by 3 weeks free living at home. Supervised challenges included two meal interventions (unannounced and late meal bolus) and a sensor calibration intervention. Primary outcome was sensor glucose time-in-range (TIR); OL run-in and E-HCL at home were compared by Wilcoxon signed-rank test. Results: Twelve adults (seven men; median [interquartile range] age 48 [39, 57] years; HbA 1c 6.8 [6.2, 7.2]%, 51 [44, 55] mmol/mol; diabetes duration 31 [13, 41] years) completed the protocol. E-HCL resulted in greater TIR (85.3 [79.4, 88.4]% vs. 75.0 [66.6, 83.7]%, P = 0.003) and lower mean sensor glucose (123.0 [119.3, 129.6] mg/dL vs. 143.5 [135.8, 154.5] mg/dL, P = 0.002) than OL. Time spent P = 0.02) with no difference in time P = 0.64). Time in CL was 99.98 [99.0, 100.0]%. All participants were satisfied using E-HCL. Conclusions: In adults with well-controlled HbA 1c levels, a prototype E-HCL resulted in high TIR, few CL exits, and positive user experiences at the expense of increased hypoglycemia (<70 mg/dL). E-HCL represents a positive step in the journey toward optimizing glucose control in people living with type 1 diabetes.Keywords
This publication has 13 references indexed in Scilit:
- Glucose Control Using a Standard Versus an Enhanced Hybrid Closed Loop System: A Randomized Crossover StudyDiabetes Technology & Therapeutics, 2019
- Safety Evaluation of the MiniMed 670G System in Children 7–13 Years of Age with Type 1 DiabetesDiabetes Technology & Therapeutics, 2019
- Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysisBMJ, 2018
- Sensor-Augmented Pump-Based Customized Mathematical Model for Type 1 DiabetesDiabetes Technology & Therapeutics, 2018
- Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 DiabetesDiabetes Technology & Therapeutics, 2017
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesJAMA, 2016
- Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient ConditionsJournal of Diabetes Science and Technology, 2016
- Home Use of an Artificial Beta Cell in Type 1 DiabetesNew England Journal of Medicine, 2015
- Effect of Insulin Feedback on Closed-Loop Glucose Control: A Crossover StudyJournal of Diabetes Science and Technology, 2012
- The Effect of Insulin Feedback on Closed Loop Glucose ControlThe Journal of Clinical Endocrinology & Metabolism, 2011